New clinical trial designs in the era of precision medicine

by Elena Garralda, Rodrigo Dienstmann, Alejandro Piris‐Giménez, Irene Braña, Jordi Rodon, Josep Tabernero
Published 2019-03-01

Genomic heterogeneity and efficacy of PI3K pathway inhibitors in patients with gynaecological cancer

by Victor Rodriguez-Freixinos, Fiorella Ruiz-Pace, Lorena Fariñas-Madrid, Ana Christina Garrido-Castro, Guillermo Villacampa, Paolo Nuciforo, Ana Vivancos, Rodrigo Dienstmann, Ana Oaknin
Published 2019-04-01

Evolution of Angiogenic Factors in Pregnant Patients with Breast Cancer Treated with Chemotherapy

by Cristina Saura, Olga Sánchez, Sandra Martínez, Carmen Domínguez, Rodrigo Dienstmann, Fiorella Ruíz-Pace, Maria Concepció Céspedes, Ángeles Peñuelas, Javier Cortés, Elisa Llurba, Octavi Córdoba
Published 2021-02-01

Molecular subtypes and the evolution of treatment management in metastatic colorectal cancer

by Giulia Martini, Rodrigo Dienstmann, Javier Ros, Iosune Baraibar, Jose Luis Cuadra-Urteaga, Francesc Salva, Davide Ciardiello, Nuria Mulet, Guillem Argiles, Josep Tabernero, Elena Elez
Published 2020-07-01

Re: Phase II trial of neoadjuvant gemcitabine and cisplatin in patients with resectable bladder carcinoma

by Daniel Herchenhorn, Rodrigo Dienstmann, Fabio A. Peixoto, Franz S. de Campos, Valdelice O. Santos, Denise M. Moreira, Hedilene Cardoso, Isabele A. Small, Carlos G. Ferreira
Published 2007-12-01

Phase II trial of neoadjuvant gemcitabine and cisplatin in patients with resectable bladder carcinoma

by Daniel Herchenhorn, Rodrigo Dienstmann, Fabio A. Peixoto, Franz S. de Campos, Valdelice O. Santos, Denise M. Moreira, Hedilene Cardoso, Isabele A. Small, Carlos G. Ferreira
Published 2007-10-01

Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterations

by David Tamborero, Carlota Rubio-Perez, Jordi Deu-Pons, Michael P. Schroeder, Ana Vivancos, Ana Rovira, Ignasi Tusquets, Joan Albanell, Jordi Rodon, Josep Tabernero, Carmen de Torres, Rodrigo Dienstmann, Abel Gonzalez-Perez, Nuria Lopez-Bigas
Published 2018-03-01

The temporal mutational and immune tumour microenvironment remodelling of HER2-negative primary breast cancers

by Leticia De Mattos-Arruda, Javier Cortes, Juan Blanco-Heredia, Daniel G. Tiezzi, Guillermo Villacampa, Samuel Gonçalves-Ribeiro, Laia Paré, Carla Anjos Souza, Vanesa Ortega, Stephen-John Sammut, Pol Cusco, Roberta Fasani, Suet-Feung Chin, Jose Perez-Garcia, Rodrigo Dienstmann, Paolo Nuciforo, Patricia Villagrasa, Isabel T. Rubio, Aleix Prat, Carlos Caldas
Published 2021-06-01

Genomic Determinants of Protein Abundance Variation in Colorectal Cancer Cells

by Theodoros I. Roumeliotis, Steven P. Williams, Emanuel Gonçalves, Clara Alsinet, Martin Del Castillo Velasco-Herrera, Nanne Aben, Fatemeh Zamanzad Ghavidel, Magali Michaut, Michael Schubert, Stacey Price, James C. Wright, Lu Yu, Mi Yang, Rodrigo Dienstmann, Justin Guinney, Pedro Beltrao, Alvis Brazma, Mercedes Pardo, Oliver Stegle, David J. Adams, Lodewyk Wessels, Julio Saez-Rodriguez, Ultan McDermott, Jyoti S. Choudhary
Published 2017-08-01

A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation

by Marta Castroviejo‐Bermejo, Cristina Cruz, Alba Llop‐Guevara, Sara Gutiérrez‐Enríquez, Mandy Ducy, Yasir Hussein Ibrahim, Albert Gris‐Oliver, Benedetta Pellegrino, Alejandra Bruna, Marta Guzmán, Olga Rodríguez, Judit Grueso, Sandra Bonache, Alejandro Moles‐Fernández, Guillermo Villacampa, Cristina Viaplana, Patricia Gómez, Maria Vidal, Vicente Peg, Xavier Serres‐Créixams, Graham Dellaire, Jacques Simard, Paolo Nuciforo, Isabel T Rubio, Rodrigo Dienstmann, J Carl Barrett, Carlos Caldas, José Baselga, Cristina Saura, Javier Cortés, Olivier Déas, Jos Jonkers, Jean‐Yves Masson, Stefano Cairo, Jean‐Gabriel Judde, Mark J O'Connor, Orland Díez, Judith Balmaña, Violeta Serra
Published 2018-12-01